Compare Neurocrine Biosciences Inc (NBIX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Financial Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $155.64 (market cap $15.91B), while Financial Select Sector SPDR Fund trades at $58.13. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | XLF | |
|---|---|---|
Market Cap | $15.91B | — |
Sector | Health | — |
52-Week High | $185.50 | $58.01 |
52-Week Low | $123.10 | $47.80 |
Enterprise Value | $15.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
XLF, the Financial Select Sector SPDR ETF, trades at $57.91, up 0.17% today, with a bullish technical signal driven by moving averages. Recent news highlights record inflows into sector ETFs and strong Q2 bank earnings, while technical indicators show overbought RSI levels. The ETF crossed above its 200-day moving average, signaling positive momentum.
The outlook for XLF is positive due to sector strength and AI-driven financial opportunities, but risks include market volatility and high expectations. Investors benefit from diversification and a dividend yield, though overbought conditions suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
